Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

"Heptovax" - A Phase II, Open-Label Trial Evaluating the Safety and Efficacy of GV1001 in Advanced Hepatocellular Carcinoma

Next Previous
X
Search
Trial Profile

"Heptovax" - A Phase II, Open-Label Trial Evaluating the Safety and Efficacy of GV1001 in Advanced Hepatocellular Carcinoma

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 02 Jun 2011

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tertomotide (Primary)
  • Indications Liver cancer
  • Focus Therapeutic Use
  • Acronyms HeptoVax
  • Sponsors Pharmexa

    • Most Recent Events

    • 17 Dec 2008 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
    • 19 Nov 2007 Interim results on the first 21 patients have been reported; final data expected by the end of the second quarter in 2008.
    • 06 Nov 2007 Status changed from recruiting to in progress. Overall, 40 patients have been enrolled. Results from the first 21 patients are expected to be reported by the end 0f 2007.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top